Literature DB >> 23370333

The innovative evolution of cancer gene and cellular therapies.

P Lam1, G Khan, R Stripecke, K M Hui, N Kasahara, K-W Peng, B-A Guinn.   

Abstract

We provide an overview of the latest developments in cancer gene therapy--from the bench to early-stage clinical trials. We describe the most recent work of worldwide teams including experienced scientists and clinicians, reflecting the recent emergence of gene therapy from the 'Valley of Death'. The treatment efficacy of clinical gene therapy has now been shown in a number of diseases including cancer and we are observing a renewed interest by big pharmaceutical and biotechnology companies most obviously demonstrated by Amgen's acquisition of Biovex for up to USD$1 billion. There is an opportunity to be cautiously hopeful regarding the future of gene therapy in the clinic and we review here some of the most recent progress in the field.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23370333     DOI: 10.1038/cgt.2012.93

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  6 in total

1.  Adenoviral-delivered HE4-HSV-tk sensitizes ovarian cancer cells to ganciclovir.

Authors:  Jennifer W Rawlinson; Kiara Vaden; Joseph Hunsaker; David F Miller; Kenneth P Nephew
Journal:  Gene Ther Mol Biol       Date:  2013

2.  Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer.

Authors:  Irina V Alekseenko; Eugene V Snezhkov; Igor P Chernov; Victor V Pleshkan; Victor K Potapov; Alexander V Sass; Galina S Monastyrskaya; Eugene P Kopantzev; Tatyana V Vinogradova; Yuri V Khramtsov; Alexey V Ulasov; Andrey A Rosenkranz; Alexander S Sobolev; Olga A Bezborodova; Anna D Plyutinskaya; Elena R Nemtsova; Raisa I Yakubovskaya; Eugene D Sverdlov
Journal:  J Transl Med       Date:  2015-03-04       Impact factor: 5.531

3.  Glycol chitosan nanoparticles as specialized cancer therapeutic vehicles: sequential delivery of doxorubicin and Bcl-2 siRNA.

Authors:  Hong Yeol Yoon; Sejin Son; So Jin Lee; Dong Gil You; Ji Young Yhee; Jae Hyung Park; Maggie Swierczewska; Seulki Lee; Ick Chan Kwon; Sun Hwa Kim; Kwangmeyung Kim; Martin G Pomper
Journal:  Sci Rep       Date:  2014-11-03       Impact factor: 4.379

Review 4.  Role of Recombinant DNA Technology to Improve Life.

Authors:  Suliman Khan; Muhammad Wajid Ullah; Rabeea Siddique; Ghulam Nabi; Sehrish Manan; Muhammad Yousaf; Hongwei Hou
Journal:  Int J Genomics       Date:  2016-12-08       Impact factor: 2.326

5.  Synergistic effects of overexpression of BMP‑2 and TGF‑β3 on osteogenic differentiation of bone marrow mesenchymal stem cells.

Authors:  Yilin Wang; Tian He; Jie Liu; Hongzhi Liu; Lugang Zhou; Wei Hao; Yujie Sun; Xin Wang
Journal:  Mol Med Rep       Date:  2016-11-22       Impact factor: 2.952

Review 6.  Gene therapy on the move.

Authors:  Kerstin B Kaufmann; Hildegard Büning; Anne Galy; Axel Schambach; Manuel Grez
Journal:  EMBO Mol Med       Date:  2013-09-17       Impact factor: 12.137

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.